These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23235567)

  • 1. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Meyer NC; Borsa N; Nasr SH; Smith RJ
    Kidney Int; 2013 Feb; 83(2):293-9. PubMed ID: 23235567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy.
    Espinosa-Figueroa JL; Cano-Megías M; Martínez-Miguel P; Velo-Plaza M
    BMJ Case Rep; 2018 Feb; 2018():. PubMed ID: 29477994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy.
    Oba Y; Mizuno H; Taneda S; Sawai T; Oda T; Ikuma D; Yamanouchi M; Suwabe T; Kono K; Kinowaki K; Ohashi K; Sawa N; Ubara Y
    CEN Case Rep; 2024 Apr; 13(2):110-116. PubMed ID: 37452997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the significance of complement-related genes mutations in atypical postinfectious glomerulonephritis: a pilot study.
    Xu F; Zhang C; Zhang M; Zhu X; Cheng S; Cheng Z; Zeng C; Jiang S
    Int Urol Nephrol; 2024 Apr; 56(4):1475-1485. PubMed ID: 37845399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quest for an intrinsic C3 activating factor in human glomerular disease.
    Roberts JL; Lewis EJ
    Surv Immunol Res; 1982; 1(2):191-8. PubMed ID: 6227068
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
    Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of C5 in Severe Acute Postinfectious Glomerulonephritis Associated With Anti-Factor H Autoantibody.
    Chehade H; Rotman S; Frémeaux-Bacchi V; Aubert V; Sadallah S; Sifaki L; Salomon R; Pascual M
    Am J Kidney Dis; 2016 Dec; 68(6):944-948. PubMed ID: 27683044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
    Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
    Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
    Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Factor B Antibodies and Acute Postinfectious GN in Children.
    Chauvet S; Berthaud R; Devriese M; Mignotet M; Vieira Martins P; Robe-Rybkine T; Miteva MA; Gyulkhandanyan A; Ryckewaert A; Louillet F; Merieau E; Mestrallet G; Rousset-Rouvière C; Thervet E; Hogan J; Ulinski T; Villoutreix BO; Roumenina L; Boyer O; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2020 Apr; 31(4):829-840. PubMed ID: 32034108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of C3 glomerulopathy in a center of expertise.
    Koopman JJE; Teng YKO; Boon CJF; van den Heuvel LP; Rabelink TJ; van Kooten C; de Vries APJ
    Neth J Med; 2019 Jan; 77(1):10-18. PubMed ID: 30774098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 glomerulopathy.
    Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
    Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
    Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
    J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.